Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
1.600
+0.005 (0.31%)
Nov 11, 2026, 11:57 AM EST - Market open
BDTX Revenue
In the year 2025, Black Diamond Therapeutics had annual revenue of $70.00M. That makes Black Diamond Therapeutics the 25,450th largest company in the world by revenue and 3,531st in the United States.
Revenue (ttm)
$70.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
21
Market Cap
91.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 70.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
BDTX News
- 20 hours ago - Black Diamond Therapeutics Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 1 day ago - Black Diamond Therapeutics’ silevertinib shows efficacy in Phase 2 trial - TheFly
- 1 day ago - Black Diamond Therapeutics price target raised to $14 from $8 at Stifel - TheFly
- 1 day ago - Black Diamond Therapeutics Transcript: Study update - Transcripts
- 1 day ago - Black Diamond Therapeutics Press release: Study update - Filings
- 1 day ago - Black Diamond Therapeutics Slides: Study update - Filings
- 1 day ago - Black Diamond Therapeutics Quarterly report: Q3 2026 - Filings
- 1 day ago - Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update - GlobeNewsWire